These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30362099)

  • 21. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.
    Costantino L; Rastelli G; Vianello P; Cignarella G; Barlocco D
    Med Res Rev; 1999 Jan; 19(1):3-23. PubMed ID: 9918192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the role of aldose reductase in ocular inflammation.
    Yadav UC; Srivastava SK; Ramana KV
    Curr Mol Med; 2010 Aug; 10(6):540-9. PubMed ID: 20642441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taxifolin Shows Anticataractogenesis and Attenuates Diabetic Retinopathy in STZ-Diabetic Rats
    Liu F; Ma Y; Xu Y
    Endocr Metab Immune Disord Drug Targets; 2020; 20(4):599-608. PubMed ID: 31656158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tonicity-responsive enhancer binding protein regulates the expression of aldose reductase and protein kinase C δ in a mouse model of diabetic retinopathy.
    Park J; Kim H; Park SY; Lim SW; Kim YS; Lee DH; Roh GS; Kim HJ; Kang SS; Cho GJ; Jeong BY; Kwon HM; Choi WS
    Exp Eye Res; 2014 May; 122():13-9. PubMed ID: 24631337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. All in the family: aldose reductase and closely related aldo-keto reductases.
    Petrash JM
    Cell Mol Life Sci; 2004 Apr; 61(7-8):737-49. PubMed ID: 15094999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
    Maccari R; Ottanà R
    J Med Chem; 2015 Mar; 58(5):2047-67. PubMed ID: 25375908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
    Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
    Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldose reductase / polyol inhibitors for diabetic retinopathy.
    Obrosova IG; Kador PF
    Curr Pharm Biotechnol; 2011 Mar; 12(3):373-85. PubMed ID: 20939801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
    Dent MT; Veves A; Tebbs SE; Gonzalez AM; Malik RA; Boulton AJ; Ward JD; Wilson RM
    Diabet Med; 1991 Dec; 8(10):911-6. PubMed ID: 1838041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of lens aldose reductase by flavonoids--their possible role in the prevention of diabetic cataracts.
    Varma SD; Kinoshita JH
    Biochem Pharmacol; 1976 Nov; 25(22):2505-13. PubMed ID: 825129
    [No Abstract]   [Full Text] [Related]  

  • 31. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent studies of aldose reductase enzyme inhibition for diabetic complications.
    Suzen S; Buyukbingol E
    Curr Med Chem; 2003 Aug; 10(15):1329-52. PubMed ID: 12871133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options.
    Srivastava SK; Ramana KV; Bhatnagar A
    Endocr Rev; 2005 May; 26(3):380-92. PubMed ID: 15814847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of aldose reductase in naphthalene cataract.
    Lee AY; Chung SS
    Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):193-7. PubMed ID: 9430562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds.
    Sever B; Altıntop MD; Demir Y; Akalın Çiftçi G; Beydemir Ş; Özdemir A
    Bioorg Chem; 2020 Sep; 102():104110. PubMed ID: 32739480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways.
    Zeng KW; Li J; Dong X; Wang YH; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):159-71. PubMed ID: 24021941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldose reductase: a window to the treatment of diabetic complications?
    Crabbe MJ; Goode D
    Prog Retin Eye Res; 1998 Jul; 17(3):313-83. PubMed ID: 9695797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldose reductase: a novel therapeutic target for inflammatory pathologies.
    Ramana KV; Srivastava SK
    Int J Biochem Cell Biol; 2010 Jan; 42(1):17-20. PubMed ID: 19778627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. WY 14,643 inhibits human aldose reductase activity.
    Klemin S; Calvo RY; Bond S; Dingess H; Rajkumar B; Perez R; Chow L; Balendiran GK
    J Enzyme Inhib Med Chem; 2006 Oct; 21(5):569-73. PubMed ID: 17194029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders.
    Srivastava SK; Yadav UC; Reddy AB; Saxena A; Tammali R; Shoeb M; Ansari NH; Bhatnagar A; Petrash MJ; Srivastava S; Ramana KV
    Chem Biol Interact; 2011 May; 191(1-3):330-8. PubMed ID: 21354119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.